

## **POLICY**

All oncology admissions and transfers are assigned to an attending physician of record who is responsible for the supervision of the care. The RTC – Inpatient Unit (VU-14) is designated as a non-COVID Surge Unit.

### **CRITERIA FOR ADMISSION TO THE RTC – INPATIENT UNIT**

#### **I. ADMISSION CRITERIA:**

- a. Previously known to a Mount Sinai Health System (MSHS) Hematology/Oncology faculty physician (i.e. followed in the outpatient practices). These patients should be receiving active cancer management, active post-treatment management or managing complications associated with cancer management at the time of admission
- b. Low acuity non-COVID oncology patients
- c. Expected LOS <6 days

#### **II. EXCLUSION CRITERIA:**

- a. Patients who tested positive for COVID-19
- b. Patient who are non-ambulatory or require two person assist
- c. Patients who require isolation beyond standard precautions
- d. Patients who require 1:1 sitter for safety and suicidal ideation
- e. Febrile neutropenia (T>38 and ANC <1000)
- f. Patients that are acutely ill (**i.e. change from baseline**) with unstable vital signs (as above in #1) and/or **severe, symptomatic** lab abnormalities (representing a change from baseline) or cancer sequelae presenting as:
  1. Requiring non-invasive oxygen support other than nasal cannula
  2. disseminated intravascular coagulation
  3. acute chest syndrome
  4. acute mental status change/neurologic symptoms
  5. superior vena cava syndrome
  6. high risk for active acute coronary syndrome
  7. high risk for active acute cerebrovascular vascular accident
  8. elevated viscosity levels and high disease burden
  9. Suspected pulmonary embolism (PE) and symptomatic
  10. Leukocytosis with blast crisis/leukostasis
  11. New onset neurological symptoms with concern for CNS leukemia/carcinomatosis or cord compression.
- g. Patients requiring the following:
  1. Chemotherapy induction
  2. Chemotherapy regimen > 6 days
  3. Patients who have previous decompensation during treatment
  4. Telemetry/cardiac monitoring
  5. Vasoactive IV medications